Application of F-18-FDG PET/CT in staging and metabolic activity assessment of multiple myeloma

Objectives: The paper of this study was to investigate the clinical value of F-18-FDG PET/CT in staging and assessing the glucose metabolic activity of multiple myeloma (MM). Methods: A total of 25 MM patients (13 males, 12 females, age: 39-67 years) newly diagnosed by Peking University First Hospital from May 2010 to April 2015 were enrolled in this retropective study. The SUVmax of each patient reflecting the metabolic activity was recorded. D-S plus staging according to F-18-FDG PET/CT was compared with the traditional D-S staging. The SUVmax and the percentage of plasmacytes of bone marrow of phase III and non-phase III (phaseIand II) according to D-S plus staging were compared. One-way analysis of variance was used to analyze the data. Results: In 25 MM patients, the range of SUVmax of lesions was 1.8-12.0 and the mean value was 5.15±2.74. According to D-S staging, the numbers of phase I, II and III were 7, 4 and 14, respectively. While the numbers were 3, 1 and 21, respectively on the results of F-18-FDG PET/CT according to D-S plus staging. Based on the D-S plus staging system, staging of 7 patients (28%, 7/25) was changed. According to the D-S plus staging system, the SUVmax between phase III and non-phase III patients was significantly different (5.75±2.54 vs 3.00±0.70, F=4.49, P0.05). Conclusion: F-18-FDG PET/CT is of great clinical importance for MM staging and metabolic activity assessment of MM.